You must RSVP to pitch or watch!
The event will start with a fireside chat with Helmy Eltoukhy, the Guardant Health CEO founder. We will discuss his journey from lab research to a building category-defining company in cancer detection.
Five biotech startups will then pitch their ideas for live, candid feedback from Helmy and Pear VC.
Helmy Eltoukhy is a biotech pioneer and the CEO founder of Guardant Health (Nasdaq: GH). He holds a PhD, MS, and BS in EE from Stanford. During his Stanford doctoral studies, he developed the first semiconductor sequencing platform and first base-calling algorithm for next-gen sequencing. In 2007, he co-founded Avantome to commercialize semiconductor sequencing and sold the company to Illumina in 2008. In 2012, Eltoukhy and AmirAli Talasaz cofounded Guardant Health, established to "forge a new frontier" in cancer detection and treatment using AI. Guardant went public on the NASDAQ in 2018, and was the first Pear VC's portfolio company to IPO.
Pear is an early stage venture capital fund based in Silicon Valley. We partner with founders from day zero to build category defining companies. Our team has founded 8 companies and we share that experience with the next generation. We have been fortunate to partner early with companies now valued at over $40B, including Doordash, Branch, Gusto, and Guardant Health. Pear portfolio biotech companies including Guardant Health, BioAge, Senti Bio, Multerra Bio, Xilis, Interface Bio, and more.